Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - cilastatin sodium 530 mg - eq. cilastatin 500 mg; imipenem monohydrate 530 mg - eq. imipenem 500 mg - powder for solution for infusion - 500 mg - 500 mg - cilastatin sodium; imipenem monohydrate 530 mg - imipenem and enzyme inhibitor

Singapore - English - HSA (Health Sciences Authority)

alliance pharm pte. ltd. - imipenem monohydrate 530mg corresponding to imipenem; sodium cilastatin 530mg corresponding to cilastatin - injection, powder, for solution - 500mg - imipenem monohydrate 530mg corresponding to imipenem 500mg; sodium cilastatin 530mg corresponding to cilastatin 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

United States - English - NLM (National Library of Medicine)

cardinal health - imipenem (unii: 71otz9ze0a) (imipenem anhydrous - unii:q20im7he75) - imipenem anhydrous 500 mg in 100 ml

Singapore - English - HSA (Health Sciences Authority)

novem pharma private limited - imipenem monohydrate 530mg corresponding to imipenem; sodium cilastatin 530mg corresponding to cilastatin - injection, powder, for solution - 500mg - imipenem monohydrate 530mg corresponding to imipenem 500mg; sodium cilastatin 530mg corresponding to cilastatin 500mg

Singapore - English - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - imipenem monohydrate 530mg/vial eqv imipenem; sodium cilastatin 530mg/vial eqv cilastatin - injection, powder, for solution - imipenem monohydrate 530mg/vial eqv imipenem 500mg/ vial; sodium cilastatin 530mg/vial eqv cilastatin 500mg/ vial

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - imipenem anhydrous (unii: q20im7he75) (imipenem anhydrous - unii:q20im7he75), cilastatin (unii: 141a6amn38) (cilastatin - unii:141a6amn38), relebactam anhydrous (unii: 1oqf7tt3pf) (relebactam anhydrous - unii:1oqf7tt3pf) - recarbrio™ is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: acinetobacter calcoaceticus-baumannii complex, enterobacter cloacae , escherichia coli , haemophilus influenzae , klebsiella aerogenes, klebsiella oxytoca, klebsiella pneumoniae, pseudomonas aeruginosa, and serratia marcescens. recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cuti), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: enterobacter cloacae , escherichia coli , klebsiella aerogenes, klebsiella pneumoniae, and pseudomonas aeruginosa . approval of this indication is based on limited clinical safety and efficacy data for recarbrio [see clinical studies (14.2)] . recarbrio is indicated in patients

Canada - English - Health Canada

sun pharma canada inc - imipenem; cilastatin (cilastatin sodium) - powder for solution - 250mg; 250mg - imipenem 250mg; cilastatin (cilastatin sodium) 250mg - carbapenems

Canada - English - Health Canada

sun pharma canada inc - imipenem; cilastatin (cilastatin sodium) - powder for solution - 500mg; 500mg - imipenem 500mg; cilastatin (cilastatin sodium) 500mg - carbapenems